A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms START
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Feb 2017 Status changed from recruiting to completed.
- 24 Dec 2016 This trial was completed in Germany (end date: 2016-12-12), according to European Clinical Trials Database.
- 11 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.